期刊文献+

激素冲击治疗活动性格雷夫斯病眼病的疗效分析 被引量:2

The clinical study of the effect of steroid pulse therapy on Graves' ophthalmopathy.
原文传递
导出
摘要 目的分析影响激素冲击治疗活动性格雷夫斯病眼病(GO)疗效的因素。方法对2003年12月至2004年12月在中山大学附属第一医院内分泌科就诊的32例初诊的GO患者进行激素冲击治疗,分析治疗有效组和无效组的临床特点。结果19例(59.4%)患者治疗后眼部症状和体征有不同程度的改善。通过分级分析发现对于病程<4个月,临床活动评分(clinical activity score,CAS)>7,治疗前甲状腺刺激素抗体(TSAb)滴度高及软组织炎症症状严重的患者疗效明显优于轻度症状者。结论活动性强、病程短、治疗前TSAb高的患者接受激素冲击治疗的效果较好。 Objective To analyse the influential factors of steroid pulse therapy on Graves' ophthalmopathy. Methods Thirty-two newly diagnosed Graves' ophthalmopathy patients were treated with intravenous glucocorticoid therapy in our hospital during 2003 - 12--2004 - 12. The clinical features between favorable response patients and no response patients were compared for evaluating related factors affecting the prognoses. Results After treatment ,59.4% cases had favorable responses,and these patients had the high titer of TSAb, CAS 〉 7 and the course of GO 〈 4 months. There were no significant differences in the distribution of age and gender. Conclusion It is very essential to properly select patients and medicine operation opportunity for turnover. We think high score of CAS, short course and high level of TSAb before treatment are the indications of good prognosis.
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2007年第3期208-210,共3页 Chinese Journal of Practical Internal Medicine
基金 广东省科委重点项目(20021901)
关键词 格雷夫斯病眼病 激素冲击治疗 疗效 Graves' ophthalmopathy Intravenous glueocorticoid therapy Prognosis
  • 相关文献

参考文献10

  • 1Bartley GB, Gorman CA. Diagnostic criteria for Graves' ophthalmopathy[ J]. Am J Ophthalmol, 1995,119:792 - 795.
  • 2Van Dyk HJ. Orbital Graves' diease: a modification of the "NOSPECS" classification [ J ]. Ophthalmology, 1981,88 : 479 -483.
  • 3Mouritis MP, Pmnmel M, Wiersinga WM, et al. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy[ J ]. Clin Endocrinol, 1997,47 ( 1 ) :9 - 14.
  • 4徐利,王琛,雒文田.用表达重组TSH受体的人胚肾细胞测定甲状腺刺激抗体和TSH刺激阻断抗体的研究[J].中华内分泌代谢杂志,2002,18(1):53-54. 被引量:12
  • 5Marcocci C, Bartalena L, Tanda ML, et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy : results of a respective, single-blind, randomized study[ J]. J Clin Endocrinol Metab,2001,86( 8 ) :3562 -3567.
  • 6Matejka G, Verges G, Vaillant JMP,et al. Intravenous Methylprednisolone pulse therapy in the treatment of Graves' ophthalmopathy.[J] Horm. Metab. Res, 1998,30(2) :93 -98.
  • 7Ohtsuka K,Sato A, Kawaguchi S, et al. Effect of high-dose intravenous steroid pulse therapy followed by 3-month oral steroid therapy for Graves' ophthalmopathy[ J]. Jpn J Ophthalmol,2002,46 (5) :563 - 567.
  • 8Macchia PE, Bagattini M, Lupoli M, et al. High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy [ J ]. J Endocrinol Invest,2001,24 ( 3 ) : 152 - 158.
  • 9马波,王从毅.托百士滴眼液治疗细菌性角膜炎临床观察[J].中国实用眼科杂志,2000,18(9):573-574. 被引量:12
  • 10Mori S, Yoshikawa N, Horimoto M, et al. Thyroid stimulating antibody in sera of Graves' ophthalmopathy patients as a possible marker for predicting the efficacy of methylprednisolone pulsetherapy [ J ]. Endocr J, 1995,42 ( 3 ) :441 - 448.

二级参考文献4

共引文献22

同被引文献19

  • 1孙治华,姚斌,翁建平.Graves眼病的诊治新进展[J].国外医学(内科学分册),2005,32(1):21-25. 被引量:22
  • 2Kahaly G,Forster G,Hansen C. Glycosaminoglycans in thyroid eye disease. Thyroid, 1998,8( 5 ) : 429-432.
  • 3Moris S, Yoshikawa N, Horimoto M, et al. Thyroid stimulating antibody in sera of Graves' ophthalmopathy patients as a possible marker for predicting the efficacy of methylprednisolone pulse therapy. Endocr J, 1995,42(3) :441-448.
  • 4Prummel MF,Suttorp-Schulten MS,Wiersinga WM,et al. A new ultrasonographic method to detect disease activity and predict response to immunosuppressive treatment in Graves ophthalmopathy. Ophthalmology, 1993,100(4) : 556-561.
  • 5Chang TC,Huang KM,Hsiao YL,et al. Relationships of orbital computed tomographic findings and activity scores to the prognosis of corticosteroid therapy in patients with Graves' ophthalmopathy. Acta Ophthalmol Scand, 1997,75(3) :301-304.
  • 6Majos A, Pajak M, Grzelak P, et al. Magnetic Resonance evaluation of disease activity in Graves' ophthalmopathy: T2-time and signal intensity of extraocular muscles. Med Sci Monit, 2007,13 (Suppl 1) : s44-s48.
  • 7Prummel MF, Gerding MN,Zonneveld FW, et at. The usefulness of quantitative orbital magnetic resonance imaging in Graves' ophthalmopathy. Clin Endocrinol (Oxf), 2001,54(2) : 205-209.
  • 8Postema PT,Krenning EP,Wijngaarde R,et aL [^111In-DTPA-D- Phe1] octreotide scintigraphy in thyroidal and orbital Graves'disease: a parameter for disease activity? J Clin Endocrinol Metab, 1994,79 (6): 1845-1851.
  • 9Doumas AS,Krassas G,Kahsas T,et al. Imaging somatostatin receptor activity in patients with active thyroid eye disease using Tc-99m depreotide. Clin Nucl Med, 2003,28(5) : 439-440.
  • 10Brauer VF,Scholz GH. Treatment of Graves' ophthalmopathy with oral or intravenous corticosteroids. Med Klin (Munich), 2004,99 (2) : 71-76.

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部